Skip to main content

Inveltys FDA Approval History

Last updated by Judith Stewart, BPharm on Aug 29, 2018.

FDA Approved: Yes (First approved August 22, 2018)
Brand name: Inveltys
Generic name: loteprednol etabonate
Dosage form: Ophthalmic Suspension
Company: Kala Pharmaceuticals, Inc.
Treatment for: Postoperative Ocular Inflammation

Inveltys (loteprednol etabonate) is a nanoparticle ocular corticosteroid formulation for the treatment of post-operative ocular inflammation and pain.

Dosage and Administration

Contraindications

Inveltys is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures.

Warnings and Precautions

Adverse Reactions

The most common adverse drug reactions were eye pain (1%) and posterior capsular opacification (1%). These reactions may have been the consequence of the surgical procedure.

Development timeline for Inveltys

DateArticle
Aug 23, 2018Approval FDA Approves Inveltys (loteprednol etabonate) for Post-Operative Inflammation and Pain Following Ocular Surgery
Jan  5, 2018Kala Pharmaceuticals Announces New Drug Application for Inveltys (KPI-121 1%) Has Been Accepted for Review by the U.S. Food and Drug Administration
Oct 25, 2017Kala Pharmaceuticals Submits NDA to U.S. Food And Drug Administration for Inveltys (KPI-121 1%)

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.